We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Protein Patterns in Blood Can Predict IBD As Early As 16 Years Before Diagnosis

By LabMedica International staff writers
Posted on 27 Nov 2024
Print article
Image: Specific protein patterns in the blood can predict IBD up to 16 years before onset (Photo courtesy of 123RF)
Image: Specific protein patterns in the blood can predict IBD up to 16 years before onset (Photo courtesy of 123RF)

Inflammatory bowel disease (IBD) is particularly challenging because it can progress for years without showing symptoms, leading to damage in the gastrointestinal tract before treatment begins. Now, scientists have discovered specific protein patterns in blood that can predict IBD up to 16 years before it is diagnosed. This is especially true for Crohn’s disease, which can be detected with remarkable accuracy.

Researchers at Örebro University (Örebro, Sweden) analyzed nearly 800 blood samples and identified distinct protein patterns that differentiate healthy individuals from those who later develop Crohn’s disease or ulcerative colitis. Their findings revealed that a particular combination of 29 proteins could predict Crohn’s disease with high accuracy. In contrast, predicting ulcerative colitis proved to be more difficult. The study showed that changes in protein patterns could be detected in individuals with Crohn’s disease as early as 16 years before diagnosis. According to the research published in Gastroenterology, the results emphasize that proteins related to intestinal barrier function and the immune system play a critical role in understanding the development of Crohn’s disease.

“We’ve taken an important step towards us being able to predict and prevent these diseases at a very early stage in the future,” said Jonas Halfvarson, professor of gastroenterology at Örebro University, and lead researcher of the study. “By discovering these markers long before symptoms make themselves known, we can potentially intervene earlier and hopefully improve quality of life for those individuals that risk developing IBD.”

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.